Premenopausal BRCA1/2-pV carriers or carriers of pV in other breast and/or ovarian cancer genes or genes of the Lynch-syndrome should be offered HRT after RRSO to counteract negative effects of estrogen deficiency. This evidence concerns the gene BRCA1 and ovarian carcinoma.